National Cancer Institute (NCI) Awards KIYATEC $1.725M to Develop Cancer Stem Cell (CSC) Expansion Technology
Contract Funds 3D Cell Culture Technology Platform to Expand CSCs for Small Cell Lung Cancer (SCLC) Model Development
GREENVILLE, SC | October 22, 2015 – KIYATEC announced today the award of a Fast Track Phase I and Phase II Small Business Innovation Research (SBIR) Contract for $1.725M from the National Cancer Institute (NCI), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH). The overall goal of the contract is to develop culture systems which can grow and maintain the rare population of malignant cells referred to by some as cancer stem cells, which are believed to lead to therapy resistance, relapse and death from metastatic disease. KIYATEC’s focus is small cell lung cancer (SCLC), one of the deadliest forms of cancer today with little advancement in treatments in 4 decades.